US 11,780,901 B2
Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
Samuel H. Gellman, Madison, WI (US); Shi Liu, Madison, WI (US); and Thomas J. Gardella, Needham, MA (US)
Assigned to Wisconsin Alumni Research Foundation, Madison, WI (US); and The General Hospital Corporation, Boston, MA (US)
Filed by Wisconsin Alumni Research Foundation, Madison, WI (US)
Filed on Sep. 24, 2020, as Appl. No. 17/31,178.
Application 17/031,178 is a continuation of application No. 16/109,114, filed on Aug. 22, 2018, abandoned.
Application 16/109,114 is a continuation in part of application No. 14/312,012, filed on Jun. 23, 2014, granted, now 10,501,518.
Claims priority of provisional application 61/940,124, filed on Feb. 14, 2014.
Claims priority of provisional application 61/838,307, filed on Jun. 23, 2013.
Claims priority of provisional application 62/548,442, filed on Aug. 22, 2017.
Prior Publication US 2021/0155666 A1, May 27, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/635 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/635 (2013.01) [A61K 38/00 (2013.01)] 20 Claims
 
1. An isolated, unnatural peptide analogue comprising:
PTH, a parathyroid hormone receptor (PTHR-1, PTHR-2) agonist-effective fragment of PTH, a parathyroid hormone related protein (PTHrP), a PTHR-1 or PTHR-2 agonist-effective fragment of PTHrP, M-PTH, a PTHR-1 or PTHR-2 agonist-effective fragment of M-PTH, abaloparatide (BA058), or a PTHR-1 or PTHR-2 agonist-effective fragment of abaloparatide, in which at least one naturally occurring (L)-α-amino acid residue at position 6 or 7 from the N-terminus is replaced with a β-amino acid residue; and
salts thereof.